About the Authors

Iris De Schutter

iris.deschutter@uzbrussel.be

Affiliation Department of Pediatric Pulmonology, Cystic Fibrosis Clinic and Pediatric Infectious Diseases, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Anne Vergison

Affiliation Pediatric Infectious Disease Department, Infection Control and Hospital Epidemiology Unit, Université Libre de Bruxelles-Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium

David Tuerlinckx

Affiliation Department of Pediatrics, Université Catholique Louvain, University Hospital Mont-Godinne, Yvoir, Belgium

Marc Raes

Affiliation Department of Pediatrics, Virga Jesse Hospital, Hasselt, Belgium

Julie Smet

Affiliations Immunobiology Clinic, Hôpital Erasme, Brussels, Belgium, Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles, Brussels, Belgium

Pierre R. Smeesters

Affiliations Bacterial Genetics and Physiology Laboratory, Université Libre de Bruxelles, Gosselies, Belgium, Murdoch Childrens Research Institute, Melbourne, Australia

Jan Verhaegen

Affiliation Department of Laboratory Medicine-Microbiology, Pneumococcal Reference Laboratory, Universitair Ziekenhuis Katholieke Universiteit Leuven, Leuven, Belgium

Françoise Mascart

Affiliations Immunobiology Clinic, Hôpital Erasme, Brussels, Belgium, Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles, Brussels, Belgium

Filip Surmont

Affiliation Pfizer Inc., Brussels, Belgium

Anne Malfroot

Affiliation Department of Pediatric Pulmonology, Cystic Fibrosis Clinic and Pediatric Infectious Diseases, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Competing Interests

The authors have read the journal's policy and have the following conflicts: This study was financially supported by Pfizer, Inc., the employer of Filip Surmont. Dr. De Schutter has been an invited speaker for Pfizer and has Cover Letter participated in advisory boards from GlaxoSmithKline Biologicals and Pfizer in the last 3 years. Dr. Vergison has received speaker and advisory board honoraria from GlaxoSmithKline Biologicals, MSD, and Pfizer in the last 3 years. Dr. Tuerlinckx has received advisory board honoraria from GlaxoSmithKline Biologicals and Pfizer in the last 3 years. Dr. Smeesters has received research funding from Pfizer. Pr. Mascart has received advisory board honoraria from Pfizer in the last 3 years. Pr. Verhaegen has received research funding from Pfizer and advisory board honoraria. Dr. Surmont was a fulltime employee of Pfizer until March 2013. Pr. Malfroot has received speaker and advisory board honoraria from GlaxoSmithKline Biologicals and Pfizer (including coordinating the advisory board of this work) in the last 3 years. Dr Smet has received speaker honoraria in the last 3 years. Dr. Raes has no conflicts of interest to declare. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: IDS AV DT MR JS PRS JV FM FS AM. Performed the experiments: IDS AV DT MR JS PRS JV FM AM. Analyzed the data: IDS AV DT MR JS PRS JV FM FS AM. Contributed reagents/materials/analysis tools: IDS AV DT MR JS PRS JV FM FS AM. Wrote the paper: IDS AM AV JS.